@article{0202cd2bd4c241b58d5e1c896bc23742,
title = "Serum levels of crushed posaconazole delayed-release tablets",
keywords = "Posaconazole, Therapeutic drug monitoring",
author = "Mason, {Mathew J.} and McDaneld, {Patrick M.} and Musick, {William L.} and Kontoyiannis, {Dimitrios P.}",
note = "Funding Information: D.P.K. acknowledges the Texas 4000 Distinguished Professorship for Cancer Research and the NIH-NCI Cancer Center CORE Support grant no. 16672. D.P.K. reports research support from Astellas Pharma and honoraria for lectures from Merck & Co., Gilead, and United Medical. D.P.K. has served as a consultant for Astellas Pharma, Cidara, Amplyx, and Mayne and on the advisory board of Merck & Co. M.J.M., P.M.M., and W.L.M. declare no conflicts of interest.",
year = "2019",
month = may,
doi = "10.1128/AAC.02688-18",
language = "English (US)",
volume = "63",
journal = "Antimicrobial agents and chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "5",
}